Keywords: FDA, Amgen, Denosumab, Cancer patients, Rotavirus vaccines, GlaxoSmithKline, Rotarix, Merck & Co, RotaTeq

Amgen files for second US approval of bone drug denosumab, aiming for cancer patient market; FDA backs rotavirus vaccines

Article | 17 May 2010

Print This

US biotechnology major Amgen says it has submitted a Biologics License Application (BLA) to the Food and Drug Administration for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in